share_log

Don't Ignore The Fact That This Insider Just Sold Some Shares In New Ray Medicine International Holding Limited (HKG:6108)

Don't Ignore The Fact That This Insider Just Sold Some Shares In New Ray Medicine International Holding Limited (HKG:6108)

不要忽視這個內幕人士剛剛出售新銳醫藥國際控股有限公司的一些股份(HKG:6108)
Simply Wall St ·  2022/04/30 06:55

We note that a New Ray Medicine International Holding Limited (HKG:6108) insider, Shenglei Qian, recently sold HK$154k worth of stock for HK$1.92 per share. However we note that the sale only shrunk their holding by 0.04%.

我們注意到一個 新銳醫藥國際控股有限公司 (港股代號:6108)內幕人士錢勝雷最近以每股 1.92 港元售出價值 15 萬港元的股票。但是我們注意到,出售僅將其持有量縮小了 0.04%。

Check out our latest analysis for New Ray Medicine International Holding

查看我們對新銳醫藥國際控股的最新分析

New Ray Medicine International Holding Insider Transactions Over The Last Year

新銳醫藥國際控股過去一年內幕交易

In fact, the recent sale by Shenglei Qian was the biggest sale of New Ray Medicine International Holding shares made by an insider individual in the last twelve months, according to our records. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (HK$0.98). So it may not tell us anything about how insiders feel about the current share price.

事實上,根據我們的記錄,錢勝雷近期的出售是一位內幕人士在過去十二個月內最大的銷售新銳醫藥國際控股股份。我們通常不喜歡看到內部人員銷售,但銷售價格越低,它就越關注我們。白銀襯裡是這種拋售發生在最新價格(0.98 港元)之上。因此,它可能無法告訴我們內部人士對當前股價的看法。

The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

下圖顯示過去一年(按公司和個人)的內幕交易。如果您單擊圖表,則可以查看所有單獨的交易,包括股價,個人和日期!

SEHK:6108 Insider Trading Volume April 29th 2022
香港聯交所:6108 內幕交易量 2022 年 4 月 29 日

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).

如果您喜歡購買內部人士購買的股票而不是賣出,那麼您可能會喜歡這個 自由 公司名單。(提示:內部人士一直在購買它們)。

Does New Ray Medicine International Holding Boast High Insider Ownership?

新銳醫藥國際控股擁有較高的內幕擁有權嗎?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. New Ray Medicine International Holding insiders own 47% of the company, currently worth about HK$766m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

查看公司的內幕股權總額可以幫助您了解它們是否與普通股東保持一致。我們通常希望看到相當高水平的內部所有權。新銳醫藥國際控股內部人士擁有該公司的 47%,根據最近的股價,目前價值約港幣 766 億元。大多數股東會很高興看到這種內幕所有權,因為它表明管理激勵措施與其他股東保持一致。

So What Do The New Ray Medicine International Holding Insider Transactions Indicate?

那麼新銳醫藥國際控股內幕交易表明什麼?

An insider hasn't bought New Ray Medicine International Holding stock in the last three months, but there was some selling. And even if we look at the last year, we didn't see any purchases. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing New Ray Medicine International Holding. Case in point: We've spotted 1 warning sign for New Ray Medicine International Holding you should be aware of.

一位內幕人士在過去三個月沒有購買新銳醫藥國際控股股票,但有一些賣。即使我們看看去年,我們也沒有看到任何購買。儘管內部人員確實擁有公司的大量股份(這很好),但我們對他們交易的分析並不能使我們對公司感到自信。除了了解正在進行的內部交易外,確定新銳醫藥國際控股所面臨的風險也是有益的。例子:我們已經發現了新銳醫藥國際控股有限公司的 1 警告標誌您應該知道的。

But note: New Ray Medicine International Holding may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

但請注意: 新銳醫藥國際控股可能不是最好的股票買。因此,請先看看這個 自由 有趣的公司列表具有高 ROE 和低債務。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

對於本文的目的,內部人員是指向相關監管機構報告其交易的個人。我們目前涉及公開市場交易和私人出售,但不涉及衍生性交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?關注內容? 取得聯繫 直接與我們聯繫。 或者,通過電子郵件發送電子郵件給編輯團隊。
這篇文章由簡單牆聖是一般性質. 我們僅使用公正的方法,根據歷史數據和分析師預測提供評論,我們的文章並不打算作為財務建議。 它並不構成購買或出售任何股票的建議,也不會考慮您的目標或您的財務狀況。我們的目標是為您帶來由基本數據驅動的長期集中分析。請注意,我們的分析可能不會考慮最新的價格敏感公司公告或定性材料。簡易華街在提及的任何股票中都沒有倉位。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論